[1] CZEPAS J. The flavonoid quercetin:possible solution for anthracycline-induced cardiotoxicity and multidrug resistance [J]. Biomed Pharmacother, 2014, 68(8):1149-1159.
[2] KHASRAW M, BELL R, DANG C. Epirubicin:is it like doxorubicin in breast cancer? A clinical review [J]. The Breast, 2012, 21(2):142-149.
[3] TSUKIGAWA K, LIAO L, NAKAMURA H, et al. Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin [J]. Cancer Sci, 2015, 106(3):270-278.
[4] SULTANA A. Division of molecular structural biology [D]. Stockholm:Karolinska Institutet, 2006.
[5] KIM B S, MOON S S, HWANG B K. Structure elucidation and antifungal activity of an anthracycline antibiotic, daunomycin, isolated from Actinomadura roseola [J]. J Agric Food Chem, 2000, 48(5):1875-1881.
[6] ZHANG S J. Studies on daunomycin analogues as new antitumor agents[D]. Hangzhou:Zhejiang University, 2001.
[7] HOFMAN J, MALCEKOVA B, SKARKA A, et al. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3 [J]. Toxicol Appl Pharmacol, 2014, 278(3):238-248.
[8] PATAN S. Cardiotoxicity: anthracyclines and long term cancer survivors [J]. Int J Cardiol, 2014, 176(3):1326-1328.
[9] GREGORIO C D E, POTENZA G, FERRARO G. Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity [J]. Int J Cardiol, 2014, 176(3):1374-1376.
[10] EKHOLM F S, BERNYI, LAGERQUIST L, et al. Cytotoxic activity of some glycoconjugates including saponins and anthracyclines [J]. Carbohydr Res, 2012, 356(1):295-298.
[11] WADLER S, FUKS J Z, WIERNIK P H. Phase I and II agents in cancer therapy:I. anthracyclines and related compounds[J]. J Clin Pharmacol, 1986, 26(7):491-509.
[12] KHEIROLOMOOM A, MAHAKIAN L M, LAI C L, et al. Copper-Doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity [J]. Mol Pharm, 2010, 7(6):1948-1958.
[13] MORO S, BERETTA G L, BEN D D, et al. Interaction model for anthracycline activity against DNA topoisomerase II [J]. Biochemistry, 2004, 43(23):7503-7513.
[14] FORREST R A, SWIFT L P, REPHAELI A, et al. Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation [J]. Biochem Pharmacol, 2012, 83(12):1602-1612.
[15] WU Q, YANG Z, NIE Y Z, et al. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches [J]. Cancer Lett, 2014, 347(2):159-166.
[16] FERREIRA R J, SANTOS D D, FERREIRA M. P-glycoprotein and membrane roles in multidrug resistance [J]. Future Med Chem, 2015, 7(7):929-946.
[17] RAJ S, FRANCO V I, LIPSHULTZ S E. Anthracycline-induced cardiotoxicity:a review of pathophysiology, diagnosis, and treatment [J]. Curr Treat Options Cardio Med, 2014, 16(1):315.
[18] HOLSTEIN S A, BIGELOW J C, OLSON R D,et al. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors [J]. Invest New Drugs, 2015, 33(3):594-602.
[19] OCTAVIA Y, TOCCHETTI C G, GABRIELSON K L, et al. Doxorubicin-induced cardiomyopathy:from molecular mechanisms to therapeutic strategies [J]. J Mol Cell Cardiol, 2012, 52(6):1213-1225.
[20] ROCHETTE L, GUENANCIA C, GUDJONCIK A,et al. Anthracyclines/trastuzumab:new aspects of cardiotoxicity and molecular mechanisms [J]. Trends Pharmacol Sci, 2015, 36(6):326-348.
[21] LOMBARDI P, ANIMATI F, CIPOLLONE A, et al. Synthesis and conformational preference of novel 8-fluoroanthracyclines [J]. Acta Biochim, 1995, 42(4):433-444.
[22] PASQUI F, CANFARINI F, GIOLITTI A, et al. Synthesis of ring a fluorinated anthracyclines [J]. Tetrahedron, 1996, 52(1):185-198.
[23] BISCARDI M, CAPORALE R, PAGLIAI G, et al. In vitro antileukemic effect of a new anthracycline analogue, MEN 11079 [J]. Leuk Res, 2003, 27(12):1125-1134.
[24] ANIMATI F, ARCAMONE F, BIGIONI M, et al. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines:influence of stereochemistry and conformation [J]. Pharmacol, 1996, 50(3):603-609.
[25] BERETTONI M, CIPOLLONE A, OLIVIERI L, et al. Synthesis of 14-fluorodoxorubicin [J]. Tetrahedron Lett, 2002, 43(15):2867-2871.
[26] ISRAEL M, MODEST E J, FREI E. N-Trifluoroacetyladri amycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin [J]. Cancer Res, 1975, 35:1365-1368.
[27] CHHIKARA B S, MANDAL D, PARANG K J. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate [J]. Med Chem, 2012, 55(4):1500-1510.
[28] CHEGAEV K, RIGANTI C, LAZZARATO L, et al. Nitric oxide donor doxorubicins accumulate into doxorubicin-resistant human colon cancer cells inducing cytotoxicity [J]. ACS Med Chem Lett, 2011, 2(7):494-497.
[29] AINA O H, LIU R, SUTCLIFFE J L, et al. From combinatorial chemistry to cancer-targeting peptides [J]. Mol Pharm, 2007, 4(5):631-651.
[30] SOUDY R, CHEN C, KAUR K J. Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells [J]. Med Chem, 2013, 56(19):7564-7573.
[31] ISHIZUMI K, OHASHI N, TANNO N. Stereospecific total synthesis of 9-aminoanthracyclines:(+)-9-amino-9-deoxydaunomycinand related compounds [J]. J Org Chem, 1987, 52(20):4477-4485.
[32] YAMAOKA T, HANADA M, ICHII S, et al. Uptake and intracellular distribution of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells [J]. Jpn J Cancer Res, 1999, 90(6):685-690.
[33] SATOUCHI M, KOTANI Y, SHIBATA T, et al. Phase Ⅲ study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer:JCOG 0509 [J]. J Clin Oncol, 2014, 32(12):1262-1268.
[34] SCHLAGE P, MEZ G, ORBN E, et al. Anthracycline-GnRH derivative bioconjugates with different linkages:synthesis, in vitro drug release and cytostatic effect [J]. J Controlled Release, 2011, 156(2):170-178.
[35] HOCHDRFFER K, AJAJ K A B U, SCHFER-OBODOZIE C, et al. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B:synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix [J]. J Med Chem, 2012, 55(17):7502-7515.
[36] DAO K L, SAWANT R R, HENDRICKS J A, et al. Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells [J]. Bioconjugate Chem, 2012, 23(4):785-795.
[37] SCHREIER V N, PETH L, ORBN E, et al. Protein expression profile of HT-29 human colon cancer cells after treatment with a cytotoxic daunorubicin GnRH-Ⅲ derivative bioconjugate [J]. PLoS One, 2014, 9(4):1-6.
[38] YAKUBOV E, BUCHFELDER M, EYPOGLU I Y,et al. Selenium action in neuro-oncology [J]. Biol Trace Elem Res, 2014, 161(3):246-254.
[39] VINCETI M, DENNERT G, CRESPI C M, et al. Selenium for preventing cancer [J]. Cochrane Db Syst Rev, 2014,3(1):1-195.
[40] TSUCHIYA T, TAKAGI Y, OK K, et al. Synthesis and antitumor activities of 7-O-(2,6-dideoxy-2-fuoro-α-L-talopyranosyl) daunomycinone and adriamycinone [J]. J Antibiot, 1986, 39(5):731-733.
[41] NAKAI K, TAKAGI Y, TSUCHIYA T. Synthesis and antitumor activity of 7-O-[2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-α-L-talopyranosyl]-daunomycinone and adriamycinone [J]. Carbohydr Res, 1999, 316(1-4):47-57.
[42] TAKAGI Y, KOBAYASHI N, CHANG M S, et al. Synthesis and antitumor activity of the 7-O-(2,6-dideoxy-2-fuoro-α-L-talopyranosyl) daunomycinone derivatives modified at C-3′ or C-4′ [J]. Carbohydr Res, 1998, 307(3-4):217-232.
[43] HORTON D, KHARE A. Inhibitory activity of four demethoxy fluorinated anthracycline analogs against five human-tumor cell lines [J]. Bioorg Med Chem Lett, 2010, 20(21):6179-6181.
[44] GRESH N, PULLMAN B, ARCAMONE F. Joint experimental and theoretical investigation of the comparative DNA binding affinities of intercalating anthracycline derivatives [J]. Lnvest New Drug, 1989, 35(2):251-256.
[45] YU S W, ZHANG G S, ZHANG W P, et al. Synthesis and biological activities of a 3′-azido analogue of doxorubicin against drug-resistant cancer cells [J]. Int J Mol Sci, 2012, 13(3):3671-3684.
[46] FANG L Y, ZHANG G S, LI C L, et al. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance [J]. J Med Chem, 2006, 49(3):932-941.
[47] CUI F L, NIU X Q, LI L Y, et al. Interaction of anthracycline 3′-azido-epirubicin with calf thymus DNAvia spectral and molecular modeling techniques [J]. J Fluoresc, 2015, 25(4):1109-1115.
[48] GENG S G, CUI Y R, LIU Q F, et al. Spectroscopic and molecular modeling study on the interaction of ctDNA with 3′-deoxy-3′-azido doxorubicin [J]. J Lumin, 2013, 141(1):144-149.
[49] CUI F L, HUI G Q, JIANG X Y, et al. Interaction of 3′-azido-3′-deamino daunorubicin with DNA:multispectroscopic and molecular modeling [J]. Int J Biol Macromol, 2012, 50(4):1121-1126.
[50] COGAN P S, KOCH T H J. Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera [J]. Med Chem, 2004, 47(23):5690-5699.
[51] SHIOSE Y, KUGA H, OHKI H, et al. systematic research of peptide spacers controlling drug release from macromolecular prodrug system, carboxymethyldextran polyalcohol#peptide#drug conjugates [J]. Bioconjugate Chem, 2009, 20(1):60-70.
[52] PAUL A, VICENT M J, DUNCAN R. Using small-angle neutron scattering to study the solution sonformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates [J]. Biomacromolecules, 2007, 8(5):1573-1579.
[53] VERONESE F M, SCHIAVON O, PASUT G, et al. PEG-doxorubicin conjugates:influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity [J]. Bioconjugate Chem, 2005, 16(4):775-784.
[54] TOMLINSON R, HELLER J, BROCCHINI S, et al. Polyacetal-doxorubicin conjugates designed for pH-dependent degradation [J]. Bioconjugate Chem, 2003, 14(6):1096-1106.
[55] ZHANG X, CHIBLI H, MIELKE R, et al. Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis -resistant cancer cells [J]. Bioconjugate Chem, 2011, 22(2):235-243.
[56] HAN M, VAKILI M R, ABYANEH H S, et al. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells [J]. Mol Pharmaceutics, 2014, 11(8):2640-2649.
[57] ZUNINO F, PRATESI G, PEREGO P. Role of the sugar moiety in the pharmacological activity of anthracyclines:development of a novel series of disaccharide analogs [J]. Biochem Pharmacol, 2001, 61(8):933-938.
[58] ZHANG G S, FANG L Y, ZHU L Z, et al. Syntheses and biological activities of disaccharide daunorubicins [J]. J Med Chem, 2005, 48(16):5269-5278.
[59] ZHU L Z, CAO X H, CHEN W L, et al. Syntheses and biological activities of daunorubicin analogs with uncommon sugars [J]. Bioorg Med Chem, 2005, 13(23):6381-6387.
[60] EKHOLM F S, SCHNEIDER G, WLFLING G, et al. An approach to the synthesis and attachment of scillabiose to steroids [J]. Steroids, 2011, 76(6):588-595.
[61] CIPOLLONE A, BERETTONI M, BIGIONI M, et al. A novel anthracycline oligosaccharides:influence of chemical modifications of the carbohydrate moiety on biological activity [J]. Bioorg Med Chem, 2002, 10(5):1459-1470.
[62] CUI F L, QIN L X, ZHANG G S, et al. Interaction of anthracycline disaccharide with human serum albumin:investigation by fluorescence spectroscopic technique and modeling studies [J]. J Pharm Biomed Anal, 2008, 48(3):1029-1036.
[63] TEVYASHOVA A, SZTARICSKAI F, BATTA G, et al. Formation of squaric acid amides of anthracycline antibiotics. Synthesis and cytotoxic properties [J]. Bioorg Med Chem Lett, 2004, 14(18):4783-4789.
[64] ZHANG G S, FANG Y L, ZHU L Z, et al. Syntheses and biological activity of bisdaunorubicins [J]. Bioorg Med Chem, 2006, 14(2):426-434.
[65] GAJEK A, DENE M, BUKOWSKA B, et al. Pro-apoptotic activity of new analog of anthracyclines-WP 631 in advanced ovarian cancer cell line [J]. Toxicol in Vitro, 2014, 28(2):273-281.
[66] SLIWINSKA A, ROGALSKA A, MARCZAK A, et al. Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death [J]. Toxicol in Vitro, 2015, 29(5):1116-1123.
[67] KRAKOVIOV H, ETRYCH T, ULBRICH K. HPMA-based polymer conjugates with drug combination [J]. Eur J Pharm Sci, 2009, 37(3-4):405-412.